Date: 2015-11-30
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Intercept Pharmaceuticals (USA - NY)
Product: INT-767
Action
mechanism: farnesoid X receptor agonist/TGR5 agonist. INT-767 is Intercept\'s second bile acid analog to enter clinical development, and is a three-fold more potent FXR agonist than obeticholic acid (OCA). INT-767 also activates TGR5, a second bile acid receptor. TGR5 has been shown to affect energy metabolism, glucose homeostasis, bile composition/secretion, and inflammation. INT-767 has potentially promising preclinical activity in both preventing and reversing organ damage due to fibrosis.
Disease:
Therapeutic area:
Country:
Trial details:
Latest
news: * On November 30, 2015, Intercept Pharmaceuticals announced the initiation of a Phase 1 study of INT-767, a dual farnesoid X receptor (FXR) and TGR5 agonist, in healthy volunteers. The goal of the Phase 1 study will be to assess safety and pharmacokinetics in a single ascending dose escalation phase followed by a multiple ascending dose phase in healthy volunteers.
